Key Highlights

  • Elevate Uranium (ASX:EL8) closed at $0.21 on 12 November 2026, down 10.64% over the session.
  • Pilot plant Stages 1 to 4 achieved about 88% cumulative mass rejection and 79% uranium recovery.
  • Agreements have been executed to lift the company's interest in the Marenica Uranium Project from 75% to 90%.

Elevate Uranium Ltd (ASX:EL8) shares closed at $0.21 on 12 November 2026, down 10.64% over the trading session, while the S&P/ASX 200 closed at 9,146.80, lower by about 6.40 points or roughly 0.07%. Elevate is a uranium exploration and development company with its Marenica Uranium Project in Namibia and its Koppies project, and it is testing its U-pgrade beneficiation process. Its latest update is the quarterly activities report dated 30 October 2026, and the share price move on 12 November is not tied to that report.

U-pgrade Pilot Plant Results

Elevate reported first pilot-scale results from its U-pgrade process in the September 2026 quarter. Stages 1 to 4 achieved cumulative mass rejection of about 88% of the original ore mass, in line with historical testing from 2013. Marenica ore was lifted from a head grade of 89 parts per million uranium to 590 parts per million across those stages, an upgrade ratio of about seven times, with 79% uranium recovery reported.

Stage 4 calcite flotation removed a carbonate mineral that interferes with acid leaching, which the company said allows a simpler leach at ambient temperature over four to six hours. Stage 5 uranium flotation was commissioned in August 2026, and integrated results across all five stages are expected in the December 2026 quarter.

Marenica and Koppies Drilling

Elevate has executed agreements to acquire a further 15% interest in Marenica Minerals, owner of the Marenica Uranium Project, which would lift its stake from 75% to 90% on completion. During the quarter the company drilled 718 holes for 31,115 metres at Marenica and 191 holes for 5,408 metres at the Namib IV resource area of the Koppies Uranium Project. Cash holdings were $22.2 million.

Sector Context

Elevate operates in the uranium segment, where prices and long-term Supply contracts influence project funding. Companies working on processing improvements for low-grade ore aim to reduce the cost of recovering uranium from feed that would otherwise be uneconomic. On 12 November the broader index was little changed, so the share price move was specific to Elevate.

Risks and Limitations

Pilot results are not yet a full-scale process, and integrated five-stage results are still to come. The Marenica Acquisition of an additional 15% interest is subject to completion, and drilling at Koppies and Marenica will require continued funding. Uranium prices are volatile, and regulatory and operating conditions in Namibia could affect timetables.

What to Watch Ahead

Investors will look for the integrated five-stage U-pgrade results expected in the December 2026 quarter, completion of the additional Marenica interest, and assay results from the recent Namib IV drilling.

Final Word

Elevate's pilot work has produced encouraging recovery and upgrade figures, and the fall in the share price on 12 November came without a new announcement that day. Integrated five-stage results due in the December quarter will be the next key data point for the process.